CC 90005

Drug Profile

CC 90005

Alternative Names: CC-90005

Latest Information Update: 22 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Celgene Corporation
  • Class Antipsoriatics
  • Mechanism of Action Protein kinase C theta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Plaque psoriasis
  • Preclinical Arthritis

Most Recent Events

  • 28 Sep 2016 Preclinical trials in Arthritis in USA (unspecified route) before September 2016
  • 28 Sep 2016 Pharmacodynamics data from a preclinical study in Arthritis presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
  • 26 Feb 2016 Celgene Corporation terminates a phase I trial in Plaque psoriasis in USA (PO) (NCT02502188)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top